Publicacións (66) Publicacións de Martín Lazaro Quintela

filter_list

2025

  1. Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish ‘Cambados annual meeting’

    Clinical and Translational Oncology

  2. Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors

    Journal of Translational Medicine, Vol. 23, Núm. 1

  3. Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

    Translational Lung Cancer Research, Vol. 14, Núm. 4, pp. 1254-1265

  4. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology, Vol. 27, Núm. 4, pp. 1383-1397

  5. Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy

    Clinical and Translational Oncology, Vol. 27, Núm. 5, pp. 2241-2255

2024

  1. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  2. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

    BMC Cancer, Vol. 23, Núm. Suppl 1

  3. Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial)

    Meeting Abstract

  4. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

  5. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

2023

  1. 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain

    Annals of Oncology

  2. 1793P PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase

    Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)

  3. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  4. Erratum: Personalized Precision Medicine for Health Care Professionals: Development of a Competency Framework (JMIR Medical Education (2023) 9 (e43656) DOI: 10.2196/43656)

    JMIR Medical Education

  5. Personalized Precision Medicine for Health Care Professionals: Development of a Competency Framework

    JMIR Medical Education, Vol. 9

  6. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2732-2748

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  3. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC

    Cancers, Vol. 14, Núm. 11

  4. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93